Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI
June 17, 2024 08:30 ET
|
Evoke Pharma, Inc.
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA...
Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference
May 16, 2024 16:02 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Announces Closing of $7.5 Million Public Offering
February 14, 2024 07:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Global Gastroparesis Treatment Market to Surpass US$ 10,726.0 Million by 2030, Says Coherent Market Insights (CMI)
August 18, 2022 09:30 ET
|
CMI
Seattle, Aug. 18, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global gastroparesis treatment market is estimated to be valued at US$ 8,061.9 million in 2022 and expected to...